Abraxis Bioscience, Inc. ABII, Abraxis BioScience's Second Quarter Financial Results.
Abraxis Bioscience, Inc.
Rochester,NY 8/27/2009 05:03 PM GMT (TransWorldNews)
Abraxis BioScience, Inc. a complete biotechnology integrated company, reported its second quarter ended June's financial results.
The exclusive rights to market ABRAXANE(R) in the U.S. has been re-acquired by the company.By beginning in 2009 the company will not recognizes deferred income related to the real co-promotion deal.Overall net revenue income for the 2009 second quarter was $85.1 million which was $77.6 million in the second quarter of 2008.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
info@stockeinstein.com
StockEinstein.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
ABII
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
